Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $8.9 million.

  • Monte Rosa Therapeutics' Change in Account Payables rose 473.11% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 892.86%. This contributed to the annual value of $6.3 million for FY2024, which is 8.58% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Change in Account Payables is $8.9 million, which was up 905.81% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Change in Account Payables peaked at $13.3 million during Q4 2024, and registered a low of -$10.9 million during Q1 2025.
  • In the last 3 years, Monte Rosa Therapeutics' Change in Account Payables had a median value of $306,000 in 2023 and averaged $810,364.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 1,756.86% in 2024, then soared by 473.11% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Change in Account Payables (Quarterly) stood at $5.8 million in 2023, then skyrocketed by 130.72% to $13.3 million in 2024, then skyrocketed by 473.11% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, -$1.1 million for Q2 2025, and -$10.9 million during Q1 2025.